What is Matrixyl 3000 used for in research and cosmetics?

Matrixyl 3000 is described as a cosmetic ingredient for aging-skin concerns such as firmness and fine lines. The source identifies it as a fixed combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, with supportive evidence that is mostly company-generated.

How is Matrixyl 3000 proposed to work?

The proposed mechanism combines two matrikine-type signals. Palmitoyl tripeptide-1 is reported to encourage fibroblast activity related to collagen, elastin, and fibronectin, while palmitoyl tetrapeptide-7 is described as reducing IL-6 signaling connected with matrix breakdown. The palmitoyl groups are included to improve topical skin compatibility and delivery.

Is Matrixyl 3000 FDA approved?

No. The supplied source lists Matrixyl 3000 as not FDA approved and describes its status as cosmetic use with wide availability.

What side effects are reported?

The source reports that Matrixyl 3000 is generally well tolerated. It also lists temporary stinging during the first week, possible breakouts in acne-prone skin, and a caution to avoid combining it with strong acids.

What dose information is available?

The source reports limited community dosing information. In research-oriented formulation context, Matrixyl 3000 is listed at 2-8% in topical serums or creams, with ongoing use described for maintained effects.

Skin & Hair Research - early research

Matrixyl 3000

Also known as: Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Pal-GHK, Pal-GQPR

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Topical palmitoylated peptide complex researched for collagen support, firmness, and aging-skin appearance.

Status

Research

Evidence level: early research

Typical dose

Limited community data available

Topical

Researched for

Advanced anti-aging, collagen synthesis, skin repair

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Limited evidence and no established human dosing

Use the tools

In plain language

Matrixyl 3000 is identified as Sederma's successor to the original Matrixyl and as a fixed topical complex of palmitoyl tripeptide-1 (Pal-GHK) plus palmitoyl tetrapeptide-7 (Pal-GQPR).
The source frames it as a cosmetic ingredient for firmness, fine lines, aging skin, collagen synthesis, and skin repair.
Status is listed as cosmetic use - widely available, with Limited Research as the evidence level and Not FDA Approved as the FDA status.
Dose information is limited in community reports; research-oriented formulation data list 2-8% in topical serums or creams.
Evidence is described as mechanistically plausible but weighted toward manufacturer-generated or sponsored human data.

How it's thought to work

Matrixyl 3000 is presented as a palmitoylated matrikine complex. Palmitoyl tripeptide-1 is reported to signal fibroblasts toward production of extracellular-matrix proteins including collagen, elastin, and fibronectin. Palmitoyl tetrapeptide-7 is described as acting on inflammatory signaling by reducing IL-6, a cytokine associated in the source with age-related matrix degradation and possible collagen glycation damage. The lipid attachments are included to help the otherwise water-soluble peptides pass into the skin when applied topically.

What the research shows

Where the research stands

The supplied research summary describes Matrixyl 3000 as biologically plausible, with findings for its components that include fibroblast proliferation, synthesis of collagen types I, III, IV, and VII, and IL-6 reduction by the tetrapeptide. It also cautions that commonly cited 12-week reports for wrinkles and skin laxity are largely manufacturer-originated or sponsored, while large independent placebo-controlled studies focused on this exact complex are described as sparse. The source states that stronger independent evidence in this family is associated with the original Pal-KTTKS Matrixyl data. The expected area of interest is skin texture and firmness rather than muscle-relaxing effects.

What it shows

✓ Early research

Limited evidence and no established human dosing

△ Limitations

Early research findings may not translate directly to human outcomes.

Bottom line: Cosmetic use - Widely available Not FDA Approved

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

Community-reported dosing data are limited and point users back to research protocols rather than a specific community dose.

Research dosing

Early researchEarly research - limited data

Doses observed in studies

2-8% in formulations

Research Literature - Observed in studies

Early research findings may not translate directly to human outcomes.

Duration: Ongoing use for maintained effects
Administration: Topical (serums, creams)

Timing & administration

Best time to take

Morning or as directed

Follow recommended protocol

Food recommendation

With or without food

Why this timing?

The source does not identify a uniquely superior application time; it indicates that regular use matters more than exact timing and that timing can vary by goal or response.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally very well-tolerated
Temporary stinging
May trigger breakouts in acne-prone skin
Avoid mixing with strong acids

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Matrixyl 3000

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Matrixyl 3000

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows